Markets:

Overview

News

Currencies

International

Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

13.12 -0.05 (-0.38%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

20 21 Next >

Viatris Misses Estimates, Cash Flow Up ↗

February 27, 2025

Viatris reported mixed results for Q4 2024, missing revenue and EPS expectations, despite noteworthy debt reduction and portfolio adjustments.

Via The Motley Fool

Get insights into the top movers in the S&P500 index of Thursday's pre-market session. ↗

February 27, 2025

Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday?

Via Chartmill

Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow

February 27, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results tomorrow before market hours. Here’s what investors should know.

Via StockStory

Viatris (NASDAQ:VTRS) Misses Q4 Revenue Estimates, Stock Drops

February 27, 2025

Medication company Viatris (NASDAQ:VTRS) fell short of the market’s revenue expectations in Q4 CY2024, with sales falling 8.1% year on year to $3.53 billion. The company’s full-year revenue guidance of...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Viatris Earnings: What To Look For From VTRS

February 26, 2025

Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow before market open. Here’s what to expect.

Via StockStory

Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks

February 21, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest

February 19, 2025

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Reasons to Sell VTRS and 1 Stock to Buy Instead

February 18, 2025

Over the past six months, Viatris’s stock price fell to $10.77. Shareholders have lost 9% of their capital, which is disappointing considering the S&P 500 has climbed by 9.3%. This might have investors...

Via StockStory

Topics Stocks

Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks

February 14, 2025

Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season.

Via StockStory

Topics Artificial Intelligence Intellectual Property

ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group

February 13, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Current Report: Viatris Inc ↗

January 31, 2025

Viatris Inc. is a wholly owned subsidiary of Pfizer that specializes in off-patent drugs. Share price fell about 4% in the past year from $11.88 to $11.41, as of Thursday’s market close.

Via Talk Markets

Topics Stocks / Equities

CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices ↗

January 06, 2025

CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions.

Via Benzinga

Topics Lawsuit

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More ↗

December 22, 2024

JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.

Via Benzinga

2 Generic Drug Stocks Ready to Surge in 2025

November 27, 2024

Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.

Via MarketBeat

Topics Government Intellectual Property

3 Chart Patterns That Cut Through The Market’s Chaos ↗

November 16, 2024

There are endless ways of analyzing price data. But the truth is, I don’t use 90% of it. What I find most useful when analyzing stock charts is pattern recognition. Today, I’ll review three of the...

Via Talk Markets

Wall Street Closes At Record Highs After Reassurance From Powell: Magnificent 7 Hit $17 Trillion, Treasury Yields Erase Post-Election Spike ↗

November 07, 2024

The U.S.

Via Benzinga

Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown ↗

November 07, 2024

Viatris reports Q3 2024 net sales of $3.74 billion, beating estimates. Adjusted EPS at $0.75 surpasses $0.68 consensus. 2024 guidance reaffirms strong growth outlook.

Via Benzinga

These 10 Stocks Were S&P 500's Worst Performers In Biden's First Year: Could Trend Continue If Harris Wins 2024 Election? ↗

November 02, 2024

The S&P 500 enjoyed a strong year in 2021, the first year with Joe Biden in the White House. Not all stocks were up and past results could show sectors to avoid ahead of the 2024 election.

Via Benzinga

Topics Stocks

FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes ↗

November 01, 2024

Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel vote against approval, with mixed expert support.

Via Benzinga

How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

October 01, 2024

How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Via News Direct

Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday? ↗

September 24, 2024

Regeneron filed an appeal after a court's decision, which was issued under seal.

Via Benzinga

EXCLUSIVE: Options Expert Warns Of 'Terrible Week' After Friday's Triple Witching ↗

September 20, 2024

CC Lagator of Options AI warns traders to expect increased volatility in the week after September's 'triple witching,' with over $5 trillion in options expiring and historical evidence of market...

Via Benzinga

Topics Artificial Intelligence Stocks

JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability ↗

September 06, 2024

JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris.

Via Benzinga

Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production ↗

September 06, 2024

Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally.

Via Benzinga

3 Top Value Stocks to Buy Right Now ↗

August 20, 2024

Value stocks offer potential for significant returns in today's overheated market.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 15, 2024

Via Benzinga

US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs ↗

August 08, 2024

Viatris reports Q2 revenue of $3.78 billion, with strong growth in Greater China and new product launches driving results. Adjusted EPS of $0.69 beats estimates, and the company raises its 2024 sales...

Via Benzinga

Why Viatris Stock Is Jumping Today ↗

August 08, 2024

Investors are applauding the healthcare company's improving growth story.

Via The Motley Fool

Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs ↗

August 06, 2024

Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells.

Via Benzinga

Topics Lawsuit

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.